Investor Relations We strive to maintain an open dialogue with the stock market, the media, customers and other interested parties. Our aim is to ensure that shareholders, analysts and investors receive continuous financial information about Scandinavian Enviro Systems AB.

Hem · Våra tjänster · Cash Management · Relationsbanken; Upcoming events. Den här sidan finns inte på ditt språk, därför visas den engelska sidan.

Our aim is to ensure that shareholders, analysts and investors receive continuous financial information about Scandinavian Enviro Systems AB. Investor relations. Our mission. Frill is fiercly on the side of its consumers and will deliver affordable healthy nutrition. Frill wants to enable consumers to make CellaVision is committed to the principles of corporate governance to promote business competitiveness as well as investor confidence. The company has applied the Swedish Code of Corporate Governance (The Code) as prescribed in the listing requirements of NASDAQ Stockholm.

Cantargia investor relations

Investors We have a clear ambition to act transparent and serve the financial market with information to support a fair valuation of the company. The company's shares are, from July 15, 2019, listed on Nasdaq First North Premier Growth Market but aim to go to the main market at Nasdaq Stockholm some time during 2021. Investor Relations We strive to maintain an open dialogue with the stock market, the media, customers and other interested parties. Our aim is to ensure that shareholders, analysts and investors receive continuous financial information about Scandinavian Enviro Systems AB. Investor relations.

Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia.

2021-04-06, Edison analysis of Cantargia https://cantargia.com/assets/uploads/Edison-Analys-Cantargia-210406.pdf. 2021-03-10, Edison analysis of Cantargia

Om Cantargia Cantargia AB (publ), reg.no. 556791-6019, är ett bioteknikbolag som utvecklar antikroppsbaserade behandlingar för livshotande sjukdomar. Utgångspunkten är proteinet IL1RAP som är involverat i ett flertal sjukdomar och där Cantargia etablerat en plattform. Huvudprojektet, Köp aktien Cantargia AB (CANTA).

2019-05-27 · STOCKHOLM, May 27, 2019 /PRNewswire/ -- Cantargia AB's ("Cantargia") interim report for first quarter 2019 is now available on the company's web page www.cantargia

Emil Nordström.

Our mission.
Journalistkårens partisympatier

Frill is fiercly on the side of its consumers and will deliver affordable healthy nutrition.

2021-03-10, Edison analysis of Cantargia Cantargia utvecklar en antikroppsbaserad behandling riktad mot målmolekylen IL1RAP som har potential att användas för ett flertal olika cancersjukdomar.
Job finder websites

online office
ekonomiska termer svenska till engelska
leasing firmabil momsfradrag
nyexaminerad byggnadsingenjör lön
patologiska
bygglov uppsala karta

I hereby agree that Cantargia AB process my personal data according to current Privacy Policy

Vinge advises Cantargia. The Vinge team includes Erik Sjöman, Christian Lindhé, Ludvig Frithiof and Sophia Reutercrona. Cantargia submits application to start new clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can Mar 10, 2021 Cantargia provides business updates at investor conferences Cantargia ligger i framkant i klassen samtidigt som jätten Novartis banar väg med en stor satsning på projektet canakinumab i lungcancer. Förutsättningarna för att träffa ett samarbete med en större partner ser därför goda ut, givet att den pågående fas IIa-studien kan visa på lovande resultat. Cantargia had a positive pre-IND meeting with FDA around the antibody CAN04. Cantargia presented novel preclinical data on antibody CAN04 at the PEGS Europe conference. Cantargia reported positive interim data from ongoing phase IIa combination study with antibody CAN04.